Biogen Idec Strikes $299M Deal for Isis Antisense Drug

The recent multi-million dollar deal between Biogen Idec and Isis Pharmaceuticals signals Biogen’s growing interest in rare diseases. Under the agreement, Biogen will provide $29 million in upfront funding to finance Isis’ antisense Spinal Muscular Atrophy (SMA) drug, which has recently shown efficacy for SMA, a genetic motor neuron disease with certain similarities to ALS. Isis is also moving forward with its antisense ALS drug under clinical development in collaboration with Genzyme.

Click here to read more.

Share this: